(Ala-triazol)Ac-Re(Arg11)CCMSH

(Ala-triazol)Ac-Re(Arg11)CCMSH is a synthetic **triazole-modified peptide/Melanocyte-stimulating hormone analog** designed to modulate biological targets with enhanced proteolytic stability and unique pharmacological properties. The structure features a triazole ring replacing an amide bond for increased stability (amide bioisostere), the incorporation of acetylated arginine at the 11th position (Arg11), and a core sequence derived from cyclic cysteine-modified α-MSH (CCMSH), a melanocortin receptor-targeting peptide. Triazole-modified peptidomimetics and related conjugates are researched for their improved bioactivity, resistance to enzymatic degradation, and have shown therapeutic promise in anticancer applications, among others. Similar triazole-modified analogs have demonstrated anticancer activity, signaling bias, and increased functional selectivity, although specific clinical indications for (Ala-triazol)Ac-Re(Arg11)CCMSH have not been published in major clinical or regulatory databases. Research into analogous triazole-modified melanocortin peptides has focused on **receptor agonism or modulation (primarily the melanocortin-1 receptor and other melanocortin receptors), with potential applications in cancer, metabolic, and pigmentary disorders**[2][3][4][5].